Cite

HARVARD Citation

    Bose, N. et al. (n.d.). Anti-beta glucan antibodies represent a mechanism-based biomarker to select patients responsive to the novel immunotherapeutic, Imprime PGG. European journal of cancer. pp. S106-S107. [Online]. 
  
Back to record